Get Coupons
Catalog No. —
|
Category: Product
—
Please wait while the product information is being retrieved.
We could not load this product.
Antibody targeting anti-ADC payload for enhanced drug delivery and therapeutic efficacy in antibody-drug conjugate applications.
$ 500.00
Anti-ADC Payload Antibodies are highly specific detection tools developed for ADC drug R&D. They precisely track the dynamic trajectory of the ADC "warhead" payload and systematically address core industry pain points in ADC development, such as imbalanced payload release, uncontrolled off-target toxicity, and non-standardized detection data, serving as the core detection reagents supporting the entire ADC development and regulatory filing process.
Anti-ADC Payload Antibodies are detection tools built for ADC drug analysis: they cover the five mainstream payloads (DM1, DXd, MMAE, MMAF, SN38), including DM1 detection antibody and DXd, MMAE, MMAF, and SN38 detection, and span the entire workflow of ADC process quality control, stability studies, PK / toxicity analysis, and clinical sample testing.
The products serve as a "molecular radar" for tracking ADC payloads. Leveraging high-specificity binding, they precisely identify and capture small-molecule toxin payloads and monitor payload in vitro stability, in vivo distribution, metabolism, and release dynamics in real time, fundamentally resolving development challenges caused by premature payload shedding (toxicity) or insufficient release (poor efficacy).
Compatible with mainstream ADC warhead types: independently developed on a mature hybridoma platform, the products fully cover the five mainstream payloads in today's ADC field — DM1, DXd, MMAE, MMAF, and SN38 — and meet the development needs of the vast majority of domestically developed and imported ADC drug candidates, with exceptional universality.
High-specificity recognition for accurate and reliable detection data
Full-workflow compatibility covering the entire ADC development cycle
Strong compliance to accelerate clinical filing
End-to-end compliance empowerment from development to filing: the products span the entire ADC drug workflow, from process quality control, formulation stability studies, pharmacokinetic analysis, and toxicity mechanism elucidation to biological analysis of clinical samples, IND filing, and Phase I / II / III clinical development, fully complying with CDE non-clinical and clinical research testing standards and comprehensively accelerating the development and commercialization of domestic ADC drugs.
Rating
Long Press to Scan QR Code
Scan QR Code
